

CONFERENCE SCHEDULE

FRIDAY, JUNE 22

- 3:00 p.m.-9:30 p.m.** **Registration**
Registration Desk B
- 6:00 p.m.-8:00 p.m.** **Welcome and Opening
Keynote Address**
Salon E
- 6:00 p.m.-6:07 p.m. **Welcome from
AACR Chief Executive Officer**
Margaret Foti, American
Association for Cancer Research,
Philadelphia, PA
- 6:07 p.m.-6:15 p.m. **Welcome from
Scientific Committee Chair**
Ari M. Melnick, Weill Cornell
Medical College, New York, NY
- 6:15 p.m.-6:45 p.m. **Keynote Address: Immunogenicity
predicts prevention**
Michael A. Caligiuri, City of Hope,
Duarte, CA
- 6:45 p.m.-7:30 p.m. **Keynote Address: CAR T for
lymphoma and beyond**
Carl H. June, University of
Pennsylvania, Philadelphia, PA
- 7:30 p.m.-8:00 p.m. **Panel discussion**
Ari M. Melnick
Michael A. Caligiuri
Carl H. June
- 8:00 p.m.-10:00 p.m.** **Opening Reception**
Salon F

SATURDAY, JUNE 23

7:00 a.m.-8:00 a.m. **Breakfast**

Salon F

7:15 a.m.-8:00 a.m. **Concurrent Sessions 1-2**

Concurrent Session 1: Canine Lymphoma as a Surrogate for Human Lymphomas: What Can We Learn from Canine Clinical Trials?

Salons B-D

Session Cochairs: Luca Aresu, University of Turin, Grugliasco, Italy, and Kristy L. Richards, Cornell University, Ithaca, NY

7:15 a.m.-8:00 a.m.

Panel discussion

Luca Aresu

Cheryl A. London,

Tufts Medical Center, Boston, MA

Laura Marconato,

Centro Oncologico Veterinario,

Sasso Marconi, Italy

Kristy L. Richards

Concurrent Session 2: What Is the Optimal Therapeutic Approach to NHL in Adolescents and Young Adults: A Discussion from the Pediatric and Adult Perspectives

Salon E

Session Chair: Lisa G. Roth, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY

7:15 a.m.-8:00 a.m.

Panel discussion

Kieron Dunleavy,

George Washington University,

Washington, DC

Lisa G. Roth

CONFERENCE SCHEDULE

- 8:00 a.m.-10:30 a.m. **Plenary Session 1:
Are We Ready for
Lymphoma MATCH Trials?**
Salon E
- Session Chair:** Anas Younes, Memorial Sloan Kettering
Cancer Center, New York, NY
- 8:00 a.m.-8:25 a.m. **Precision medicine based on the
genetic taxonomy of DLBCL**
Louis M. Staudt, National Cancer
Institute, Bethesda, MD
- 8:25 a.m.-8:50 a.m. **How to design a MATCH trial
for lymphoma**
Anas Younes
- 8:50 a.m.-9:15 a.m. **Practical considerations for using
genome sequencing data for
patient selection**
David W. Scott, BC Cancer Agency,
Vancouver, BC, Canada
- 9:15 a.m.-9:40 a.m. **Molecular typing in DLBL: Subset
and match?**
Peter W. M. Johnson, University
of Southampton, Southampton,
United Kingdom
- 9:40 a.m.-9:55 a.m. **Utilizing genomic sequencing
from clinical assays in
lymphoma management**
Connie Batlevi, Memorial Sloan
Kettering Cancer Center,
New York, NY
- 9:55 a.m.-10:30 a.m. **Panel discussion**
Connie Batlevi
Peter W.M. Johnson
David W. Scott
Louis M. Staudt
Anas Younes
- 10:30 a.m.-11:00 a.m. Break**
Salons A-E Foyer

11:00 a.m.-11:30 a.m. Spotlight on Proffered Papers Session 1

(from posters in Session A)
Salon E

11:00 a.m.-11:15 a.m. Drugs in the curative RCHOP combination exhibit low cross-resistance but not pharmacologic synergy

Adam C. Palmer, Harvard Medical School, Boston, MA

11:15 a.m.-11:30 a.m. MHC class II expression is associated with a distinct mutational profile and immune cell landscape of the microenvironment in GCB-DLBCL

Daisuke Ennishi, BC Cancer Agency, Vancouver, BC, Canada

11:45 a.m.-1:45 p.m. Poster Session A / Lunch

Salon F

Lymphoid Cancers 1

Basic and Translational Science 1

Other Topics

Therapeutics and Clinical Trials in Lymphoma 1

2:00 p.m.-4:00 p.m. Plenary Session 2: Targeting the Epigenome of DLBCL

Salon F

Session Cochairs: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland, and Laura Pasqualucci, Columbia University Institute for Cancer Genetics, New York, NY

2:00 p.m.-2:25 p.m. DNA and histone methylation as therapeutic targets in lymphoma

Ari M. Melnick, Weill Cornell Medical College, New York, NY

CONFERENCE SCHEDULE

Plenary Session 2 (cont'd)

- 2:25 p.m.-2:50 p.m. **Targeting EZH2 in lymphoma**
Vincent Ribrag, Institut Gustave-Roussy, Villejuif, France
- 2:50 p.m.-3:15 p.m. **Germinal center-derived lymphomas: At the intersection of genetics and epigenetics**
Laura Pasqualucci
- 3:15 p.m.-3:40 p.m. **BET inhibitors in lymphoma**
Francesco Bertoni
- 3:30 p.m.-4:00 p.m. **Panel discussion**
Francesco Bertoni
Ari M. Melnick
Laura Pasqualucci
Vincent Ribrag
- 4:00 p.m.-4:30 p.m. **Break**
Salons A-E Foyer
- 4:30 p.m.-6:30 p.m. **Plenary Session 3: Can Liquid Biopsies Replace Tissue and Be Used to Guide Clinical Decisions?**
Salon E
- Session Chair:** Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland
- 4:30 p.m.-5:00 p.m. **Circulating tumor DNA to monitor treatment response and detect resistant clones in indolent lymphoproliferative diseases treated with novel therapies**
Constantine S. Tam, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

- 5:00 p.m.-5:30 p.m. **Tumor fingerprints in the liquid biopsy: Immunoglobulin gene rearrangement or CAPP-seq?**
Wyndham H. Wilson, National Cancer Institute, Bethesda, MD
- 5:30 p.m.-6:00 p.m. **Use of circulating tumor DNA to genotype aggressive lymphomas**
Davide Rossi
- 6:00 p.m.-6:30 p.m. **Panel discussion**
Lee M. Greenberger, The Leukemia & Lymphoma Society, Rye Brook, NY
Davide Rossi
Constantine S. Tam
Wyndham H. Wilson
- 6:30 p.m. **Dinner on own**

SUNDAY, JUNE 24

- 7:00 a.m.-8:00 a.m. **Breakfast**
Salon F
- 7:15 a.m.-8:00 a.m. **Concurrent Sessions 3-4**
- Concurrent Session 3: What Is the Current Role and Impact of CRISPR Screening to Define Therapeutic Targets in Lymphoma?**
Salons B-D
- Session Chair:** Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, New York, NY

CONFERENCE SCHEDULE

Concurrent Session 3 (*cont'd*)

7:15 a.m.-7:30 a.m. **Using in vivo CRISPR-based screening to identify lymphoma drug targets**
Michael T. Hemann, David H. Koch
Institute for Integrative Cancer
Research at MIT, Cambridge, MA

7:30 a.m.-7:45 a.m. **Title to be announced**
Sandeep S. Dave, Duke University,
Durham, NC

7:45 a.m.-8:00 a.m. **Crispr-Cas9 screens interrogate lymphoma biology and lead to therapies**
Hans-Guido Wendel

Concurrent Session 4: Genetic and Molecular Heterogeneity between Western and Asian Lymphoma Patients

Salon E

Session Chair: Wei-Li Zhao, Ruijin Hospital, Shanghai
Institute of Hematology, Shanghai, China

7:15 a.m.-7:30 a.m. **Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma: Insights for novel targeted therapies**
Qiang Pan-Hammarström,
Karolinska Institute, Stockholm,
Sweden

7:30 a.m.-7:45 a.m. **The genetics of marginal zone lymphomas**
Davide Rossi, Oncology Institute of
Southern Switzerland and Institute
of Oncology Research, Bellinzona,
Switzerland

7:45 a.m.-8:00 a.m. **Precise classification and treatment of NK/T and T-cell lymphoma**
Wei-Li Zhao

8:00 a.m.-10:30 a.m. Plenary Session 4: Will CAR T Cells Replace BMT as a Modality for NHL?

Salon E

Session Chair: Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, NY

8:00 a.m.-8:30 a.m. Contemporary salvage therapy and autologous transplantation for relapsed and primary refractory DLBCL: The low bar has been firmly set

Craig S. Sauter, Memorial Sloan Kettering Cancer Center, New York, NY

8:30 a.m.-9:00 a.m. Clinical overview of CAR T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: Promise and limitations

Michael R. Bishop, University of Chicago, Chicago, IL

9:00 a.m.-9:30 a.m. Next-gen T cells

Renier J. Brentjens

9:30 a.m.-10:00 a.m. CARS versus autos or CARS plus autos?

Stephen J. Forman, City of Hope, Duarte, CA

10:00 a.m.-10:30 a.m. Panel discussion

Michael R. Bishop
Renier J. Brentjens
Stephen J. Forman
Craig S. Sauter

10:30 a.m.-11:00 a.m. Break

Salons A-E Foyer

CONFERENCE SCHEDULE

- 11:00 a.m.-11:30 a.m. Spotlight on Proffered Papers Session 2**
(from posters in Session B)
Salon E
- 11:00 a.m.-11:15 a.m. **Lenalidomide treatment restores in vivo T-cell activity in relapsed/refractory FL and DLBCL**
Cedric Menard, University of Rennes, Rennes, France
- 11:15 a.m.-11:30 a.m. **Anti-CD37 chimeric antigen receptor T cells: A new potential therapeutic option for non-Hodgkin lymphoma**
Irene Scarfo, Massachusetts General Hospital Cancer Center, Charlestown, MA
- 11:45 a.m.-1:45 p.m. Poster Session B / Lunch**
Salon F
- Therapeutics and Clinical Trials in Lymphoma 2
- Lymphoid Cancers 2
- Pathology and Classification of Lymphomas
- 2:00 p.m.-4:00 p.m. Plenary Session 5: The Significance of Targeting the Microenvironment in Lymphoma**
Salon E
- Session Chair:** Karin Tarte, University of Rennes, Rennes, France
- 2:00 p.m.-2:30 p.m. **Ex vivo lymphoid tissue microenvironments to model epigenetics and signaling in healthy and malignant B cells**
Ankur Singh, Cornell University, Ithaca, NY

- 2:30 p.m.-3:00 p.m. **Dissecting microenvironmental cues that promote B-cell lymphoma growth in secondary lymphoid organs**
Uta E. Höpken, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
- 3:00 p.m.-3:30 p.m. **Targeting cancer-associated fibroblasts to promote antitumor immunity**
Hélène Salmon, Icahn School of Medicine at Mount Sinai, New York, NY
- 3:30 p.m.-4:00 p.m. **Panel discussion**
Uta E. Höpken
Hélène Salmon
Ankur Singh
Karin Tarte
- 4:00 p.m.-4:30 p.m. **Break**
Salons A-E Foyer
- 4:30 p.m.-6:30 p.m. **Plenary Session 6: Follicular Lymphoma: When to Treat and How to Define Early Disease**
Salon E
- Session Chair:** Bertrand Nadel, Centre d'Immunologie de Marseille-Luminy, Marseille, France
- 4:30 p.m.-4:55 p.m. **Committed precursor cells (CPC) and follicular lymphoma genesis**
Bertrand Nadel
- 4:55 p.m.-5:20 p.m. **Insights into early and late steps of follicular lymphoma pathogenesis from genomic studies**
Robert Kridel, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

CONFERENCE SCHEDULE

Plenary Session 6 *(cont'd)*

5:20 p.m.-5:45 p.m. **Clinical and biologic criteria for treatment decision in follicular lymphoma**

Gilles Salles, Lyon-Sud Charles Mérieux Medical School, Pierre Bénite, France

5:45 p.m.-6:10 p.m. **Front-line chemotherapy-free treatments for follicular lymphoma?**

Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

6:10 p.m.-6:30 p.m. **Panel discussion**

Robert Kridel
Bertrand Nadel
Gilles Salles
Emanuele Zucca

6:30 p.m. Dinner on own

MONDAY, JUNE 25

7:00 a.m.-8:00 a.m. Breakfast

Salon F

7:15 a.m.-8:00 a.m. Concurrent Sessions 5-6

Concurrent Session 5: What Is the Molecular Basis and Most Promising Road towards Molecular Targeted Therapies for Double-Hit Lymphoma?

Salons B-D

Session Chair: David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA

- 7:15 a.m.-7:25 a.m. **The laboratory challenge of double-hit lymphoma**
David M. Weinstock
- 7:25 a.m.-7:35 a.m. **The clinical challenge of double-hit lymphoma**
Philippe Armand, Dana-Farber Cancer Institute, Boston, MA
- 7:35 a.m.-8:00 a.m. **Panel discussion**
Philippe Armand
David M. Weinstock

Concurrent Session 6: What Do Mutation Profiles Teach Us about Rare versus Common Forms of Lymphoma?

Salon E

Session Chair: Sandeep S. Dave, Duke University, Durham, NC

- 7:15 a.m.-7:25 a.m. **Rare vs. common: Using genomic discoveries for a unified view of lymphoma**
Sandeep S. Dave
- 7:25 a.m.-7:35 a.m. **Pathways to clinical translation of genetic discoveries**
Eric D. Hsi, The Cleveland Clinic, Cleveland, OH
- 7:35 a.m.-8:00 a.m. **Panel discussion**
Sandeep S. Dave
Eric D. Hsi

CONFERENCE SCHEDULE

8:00 a.m.-10:30 a.m. **Plenary Session 7: How Do Clonal Dynamics and Tumor Heterogeneity Factor into Clinical Outcome and Therapy?**
Salon E

Session Chair: Dan A. Landau, Weill Cornell Medical College, New York, NY

8:00 a.m.-8:30 a.m. **3'-UTR disruption of PD-L1 in malignant lymphomas**
Seishi Ogawa, Kyoto University Graduate School of Medicine, Kyoto, Japan

8:30 a.m.-9:00 a.m. **Actionable molecular heterogeneity in DLBCL**
Bjoern Chapuy, Dana-Farber Cancer Institute, Boston, MA

9:00 a.m.-9:30 a.m. **Epigenetic determinants of normal and malignant somatic evolution**
Dan A. Landau

9:30 a.m.-9:45 a.m. **Ibrutinib does not suppress clonal evolution in high-risk chronic lymphocytic leukemia**
Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland

9:45 a.m.-10:00 a.m. **Genetic landscape of extranodal marginal zone (MALT) lymphomas**
Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland

10:00 a.m.-10:30 a.m. **Panel discussion**
Francesco Bertoni
Bjoern Chapuy
Dan A. Landau
Seishi Ogawa
Davide Rossi

10:30 a.m.-11:00 a.m. Break

Salons A-E Foyer

11:00 a.m.-11:30 a.m. Spotlight on Proffered Papers Session 3

(from posters in Session C)

Salon E

11:00 a.m.-11:15 a.m. HSF1 orchestrates a prolymphomagenic microenvironment through matrix remodeling and deficient lymphoma immunity

Jude M. Phillip, Weill Cornell Medicine, New York, NY

11:15 a.m.-11:30 a.m. The ETS inhibitors YK-4-279 and TK-216 synergize with lenalidomide via SPIB downregulation in diffuse large B-cell lymphoma of the activated B cell-like type (ABC DLBCL)

Filippo Spriano, Institute of Oncology Research, Bellinzona, Switzerland

11:45 a.m.-1:45 p.m. Poster Session C / Lunch

Salon F

Basic and Translational Science 2

Diagnostic and Prognostic Biomarkers

Ethnicity as a Risk Factor in Cancer Disparities

Therapeutics and Clinical Trials in Lymphoma 3

CONFERENCE SCHEDULE

2:00 p.m.-4:00 p.m.

Plenary Session 8: What Is the Role for Checkpoint Protein Functionality and Therapeutic Blockade in Lymphoma?

Salon E

Session Chair: Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA

2:00 p.m.-2:30 p.m.

Exploiting epigenetic and immune vulnerabilities in lymphoma

Ricky W. Johnstone, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

2:30 p.m.-3:00 p.m.

Targetable genetic bases of immune evasion in lymphoma

Margaret A. Shipp

3:00 p.m.-3:30 p.m.

In situ vaccination for lymphoma

Ronald Levy, Stanford University, Stanford, CA

3:30 p.m.-4:00 p.m.

Panel discussion

Ronald Levy
Margaret A. Shipp

4:00 p.m.-4:30 p.m.

Break

Salons A-E Foyer

4:30 p.m.-6:30 p.m.

Plenary Session 9: How Can We Improve the Outcome of Patients with PTCL?

Salon E

Session Chair: Kerry Savage, University of British Columbia, Vancouver, BC, Canada

4:30 p.m.-4:55 p.m.

How do we raise the therapeutic bar in PTCLs?

Kerry Savage

4:55 p.m.-5:20 p.m.

Genomics and pathobiology of PTCL

Wing C. Chan, City of Hope, Duarte, CA

5:20 p.m.-5:45 p.m. **PDX models in T-cell lymphoma**
David M. Weinstock, Dana-Farber
Cancer Institute, Boston, MA

5:45 p.m.-6:00 p.m. **Novel drug combinations**
Neha Mehta-Shah, Washington
University Medical School,
St. Louis, MO

6:00 p.m.-6:30 p.m. **Panel discussion**
Wing C. Chan
Neha Mehta-Shah
Kerry Savage
David M. Weinstock

6:30 p.m. Dinner on own

TUESDAY, JUNE 26

7:00 a.m.-8:00 a.m. Breakfast
Salons B-D

8:00 a.m.-10:00 a.m. Keynote Lectures
Salon E

8:00 a.m.-8:45 a.m. **Immune checkpoint blockade
in cancer therapy: New insights,
opportunities, and prospects for
cures**
James P. Allison, The University of
Texas MD Anderson Cancer Center,
Houston, TX

8:45 a.m.-9:30 a.m. **Targeting Achilles heels in
multiple myeloma**
Kenneth C. Anderson, Dana-Farber
Cancer Institute, Boston, MA

CONFERENCE SCHEDULE

Keynote Lectures *(cont'd)*

9:30 a.m.-10:00 a.m. **Panel discussion**
James P. Allison
Kenneth C. Anderson
Ari M. Melnick

10:00 a.m.-10:15 a.m. **Break**
Salons A-E Foyer

10:15 a.m.-12:15 p.m. **Plenary Session 10:
Transforming First-Line
Therapy for Hodgkin and
Non-Hodgkin Lymphoma**
Salon E

Session Chair: Thomas E. Witzig, Mayo Clinic College of
Medicine, Rochester, MN

10:15 a.m.-10:45 a.m. **Standard of care in 2018 for
DLBCL: Setting the stage for the
next NCTN trials**
Thomas E. Witzig

10:45 a.m.-11:15 a.m. **Transforming the front-line care
of PTCL**
Owen A. O'Connor, Columbia
University Medical Center, New
York, NY

11:15 a.m.-11:45 a.m. **Title to be announced**
Kerry Savage, University of British
Columbia, Vancouver, BC, Canada

11:45 a.m.-12:15 p.m. **Panel discussion**
Owen A. O'Connor
Kerry Savage
Thomas E. Witzig

12:15 p.m.-12:30 p.m. **Meeting Highlights: Promise
for the Future**
Salon E

Ari M. Melnick, Weill Cornell
Medical College, New York, NY